Allosteric modulators for
human health
About us
Addex Corporate Presentation
Overview
Our people
Executive Officers
Non-Executive Directors
Contact
Privacy Policy
Careers
Pipeline
Clinical and Pre-Clinical Pipeline
Research And Development
Technology
Allosteric modulation
Publications
Partners & collaboration
Investors
Addex corporate Presentation
Stock Data
Press releases
Ad hoc announcements (Art. 53 L.R)
Events
Financial Reports
Analyst Reports
General Meetings
SEC / SIX Filings
Guide to US ADSS for Six Shareholders
Register for email news
Corporate Governance
Contact
Media
Press releases
Contact
Press releases
All Years
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
Please select year
11.02
2023
Addex Announces Participation in the BIO-Europe 2023 Conference
10.20
2023
Addex Completes ADS Ratio Change
10.06
2023
Addex Announces Plan to Implement ADS Ratio Change
09.20
2023
Addex mGlu2 NAM Cognition Program Receives €4 Million Grant
09.06
2023
Addex Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference
09.05
2023
Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024
09.04
2023
Addex’s Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brain
08.10
2023
Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Update
08.04
2023
Addex Therapeutics to Release Half-Year 2023 Financial Results and Host Conference Call on August 10, 2023
08.03
2023
Addex GABAB Positive Allosteric Modulator Program to Receive Additional CHF 2.7 million from Indivior in Extended Substance Use Disorder Research Collaboration
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
Next
Back